Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN deals

RegulatoryapprovedNegative

AI Analysis

Summary

Novartis and BMS paused CAR-T trials due to safety signals, while Revolution Medicines achieved early FDA approval for a pancreatic cancer treatment. BioNTech suspended a mid-stage mRNA cancer trial following futility analysis, and nine biopharma companies joined Trump's Most Favored Nation pricing scheme.

Clinical Trial Data

Phase

mid-stage

Primary Endpoint

Not Met

Outcome Details

Revolution Medicines' pancreatic cancer drug received early FDA approval

Importance:7/10

Sentiment:

-0.60

CAR-Tsafety concernstrial pausedFDA approvalpancreatic cancermRNAfutility analysisdrug pricing

Related Companies

$NVS $BMY $RVMD $BNTX

Read the original article

Published by BioSpace on September 2, 2026 9:52 AM

Read Original